Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
September 10 2021 - 7:30AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
the appointment of Deborah Dunsire, M.D., to the Company’s Board of
Directors. Dr. Dunsire is a highly respected industry veteran with
more than 30 years of clinical, commercial, and international
management experience within the life sciences industry.
“Deborah is a phenomenal leader with a track record of creating
value through successful development and commercialization of
life-changing new therapies for people with cancer and other
serious diseases,” said Nancy Simonian, M.D., Chief Executive
Officer of Syros. “Her global commercial expertise, oncology
R&D experience, and unwavering commitment to patients will be
invaluable to Syros as we continue to advance our targeted
hematology and CDK7 programs to market. We are thrilled to welcome
Deborah to our board.”
Dr. Dunsire currently serves as President and Chief Executive
Officer of H. Lundbeck A/S, a global pharmaceutical company focused
exclusively on treatments for brain disease. She has held the
position since September 2018. She previously served as President
and Chief Executive Officer and a Director of Xtuit
Pharmaceuticals, Inc., a private biopharmaceutical company, from
January 2017 to March 2018. Prior to her position at Xtuit, she
served as President and Chief Executive Officer and a Director of
FORUM Pharmaceuticals Inc., a private pharmaceutical company, from
July 2013 to May 2016. Prior to FORUM, Dr. Dunsire worked for
Takeda Pharmaceutical Company Limited as a corporate officer from
June 2010 to June 2011 and a Director from June 2011 to June 2013.
She served as President, Chief Executive Officer and a Director of
Millennium Pharmaceuticals, Inc. between 2005 and 2008, when it was
acquired by Takeda, and then as President and Chief Executive
Officer of Millennium: The Takeda Oncology Company after the
acquisition between 2008 and 2013. Prior to Millennium, Dr. Dunsire
held various roles of increasing responsibility at Novartis Pharma
AG between 1988 and 2005. She currently serves as a Board member of
Ultragenyx Pharmaceutical Inc. and previously served on the boards
of Alexion Pharmaceuticals and Allergan. Dr. Dunsire obtained an
MBBCh from the University of the Witwatersrand in South Africa.
“Syros has all the elements for building an enduring company –
programs with the potential to set new standards of care for
patients, a discovery engine to continue to fuel its pipeline, and
great people,” said Dr. Dunsire. “I look forward to working with
the board and the leadership team to accelerate Syros’ progress
toward becoming a fully integrated biopharmaceutical company with
medicines that make a profound difference for patients.”
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases. For more information,
visit www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding Syros’
ability to advance its clinical programs and to develop therapies
to benefit patients. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,”
‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’
‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various important
factors, including Syros’ ability to: advance the development of
its programs, including its targeted hematology and CDK7 programs,
under the timelines it projects in current and future clinical
trials; demonstrate in any current and future clinical trials the
requisite safety, efficacy and combinability of its drug
candidates; replicate scientific and non-clinical data in clinical
trials; successfully develop a companion diagnostic test to
identify patients with the RARA biomarker; obtain and maintain
patent protection for its drug candidates and the freedom to
operate under third party intellectual property; obtain and
maintain necessary regulatory approvals; identify, enter into and
maintain collaboration agreements with third parties, including its
ability to perform under its collaboration agreements with Incyte
Corporation and Global Blood Therapeutics; manage competition;
manage expenses; raise the substantial additional capital needed to
achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies;
risks described under the caption “Risk Factors” in Syros’ Annual
Report on Form 10-K for the year ended December 31, 2020 and
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021,
each of which is on file with the Securities and Exchange
Commission; and risks described in other filings that Syros makes
with the Securities and Exchange Commission in the future. In
addition, the extent to which the COVID-19 outbreak continues to
impact our workforce and our discovery research, supply chain and
clinical trial operations activities, and the operations of the
third parties on which we rely, will depend on future developments,
which are highly uncertain and cannot be predicted with confidence,
including the duration and severity of the outbreak, additional or
modified government actions, and the actions that may be required
to contain the virus or treat its impact. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Syros expressly disclaims any obligation to update
any forward-looking statements, whether because of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005024/en/
Media Naomi Aoki Syros Pharmaceuticals 617-283-4298
naoki@syros.com
Investor Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024